Dyne Therapeutics (DYN) Stifel 2025 Healthcare Conference summary

Strategic vision and pipeline progress

• Focused on functional improvement in neuromuscular diseases, targeting DMD and DM1 with a novel antibody fragment platform.

• Two lead medicines are advancing toward registration: DMD program fully enrolled for accelerated approval, DM1 in ongoing registrational cohort.

• Anticipates launching DMD therapy in early 2027 and DM1 in early 2028, with FSHD timelines expected for 2026.

• Plans to expand DMD franchise to additional exons, potentially covering 30-40% of patients, pending regulatory efficiency.

Clinical data and regulatory outlook

• DMD pivotal readout expected soon, with primary endpoint of dystrophin increase; prior data showed 8-9% dystrophin (muscle-adjusted), far exceeding current therapies.

• Functional improvements observed in stride velocity, time to rise, NSAA, and 10m walk/run, with sustained benefit up to 18 months.

• European regulators accept stride velocity 95th centile as a validated endpoint; company plans robust phase 3 for EU approval.

• Safety profile at 20 mg/kg remains favorable after prior SAEs at higher dose; ongoing monitoring with update expected in December.

Commercial and operational readiness

• Commercial team with Spinraza launch experience is preparing for targeted rollout at 100 key centers.

• Robust supply chain and manufacturing infrastructure established, leveraging Biogen expertise.

• DMD market opportunity includes 1,500-1,600 Exon 51 patients in the US, with potential for straightforward switches from existing therapies.

• DM1 market estimated at 30,000-40,000 patients, with broad eligibility due to disease heterogeneity and CNS involvement.